Bibliography
- Murphy RL, RFS-AMDX-203 Team. Amdoxovir combined with lowd Dose AZT for HIV-1 therapy [abstract 45]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Asif G, Hurwitz SJ, Tharnish PM, et al. Lack of pharmacokinetic interaction for low and normal dose zidovudine with amdoxovir in HIV-1 infected individuals [abstract 71]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Ray AS, LaFlamme G, Grant D, et al. Low potential for class related toxicity of next generation nucleotide analog GS-9148 [abstract 47]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Lefebvre E. A new era in HIV-antiretroviral therapy: darunavir, etravirine and TMC278 [abstract 46]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Lori F, Stevens M. Development of VS411, a virostatic drug fixed dose combination (FDC) designed to inhibit both HIV and immune hyperactivation [abstract 11]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Jacobson JM, Thompson MA, Fischl MA, et al. Antiviral activity and tolerability of PRO 140, a humanized monoclonal antibody to CCR 5 [abstract 75]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Mayers D, Murphy R, Zala C, et al. IDX899: a novel once-a-day second generation NNRT I for the treatment of HIV/AIDS [abstract 43]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol1996;70(10):7108-15
- Ewart GD, Nasr N, Naif H, et al. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob Agents Chemother2004;48(6):2325-30
- Khoury G, Ewart G, Luscombe C, et al. Inhibiting Vpu function with the novel compound BIT225 results in inhibition of HIV-1 release from human macrophage reservoirs [abstract 12]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Castor TP, Munoz MA, Moreno S, Munoz E. Combination therapy for treating HIV latency [abstract 16]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Hartman TL, Buckheit Jr RW. Inhibition of late stage events in HIV-1 replication: discovery and development of therapeutic compounds with effects on viral RNA synthesis which potentially target rev function [abstract 17]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Buckheit Jr Rw, Hartman TL, Yang L, Watson KM. Development of pyrimidinedione NNRT is with a high genetic barrier to resistance [abstract 10]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
- Watson KM, Yang L, Buckheit CE, Buckheit Jr RW. Development of the dual-acting pyrimidinedione IQP0528 as a vaginal topical anti-HIV microbicide [abstract 28]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico